Collectively, the co-occurrence of PIK3CA and KRAS has implications for targeted therapies, as treatments targeting PIK3CA-mutant CRC must also be effective against tumors harboring both PIK3CA and KRAS mutations to achieve optimal therapeutic outcomes. The gene discussed is KRAS; the disease is colorectal carcinoma.